Eledon Pharmaceuticals, Inc. Common Stock (ELDN) Stock
Key stats
- Market cap
- $216.97M
- Price / Earnings ratio
- -2.2x
- EPS (TTM)
- -$0.91
- Volume
- Loading
- 52-week high
- $4.49
- 52-week low
- $1.35
Source: third-party data provider, as of November 13, 2026
Compare with ELDN
Recent news

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
ELDN

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
ELDN

Best Momentum Stocks to Buy for July 14th
Best Momentum Stocks to Buy for July 14th
ELDN

New Strong Buy Stocks for July 14th
New Strong Buy Stocks for July 14th
ELDN
Technical indicators
- RSI 14
- 52.33
- MACD 12/26/9
- 0.05
- EMA 9 of MACD
- 0.01
- MACD histogram
- 0.04
- SMA 50
- $2.59
- Price above SMA 50
- EMA 50
- $2.69
- Price below EMA 50
- SMA 200
- $3.13
- Price below SMA 200
- EMA 200
- $2.77
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
No analyst data available
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial
ELDN

Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
Is Eledon Pharmaceuticals (ELDN) Outperforming Other Medical Stocks This Year?
ELDN

Best Momentum Stocks to Buy for July 14th
Best Momentum Stocks to Buy for July 14th
ELDN

New Strong Buy Stocks for July 14th
New Strong Buy Stocks for July 14th
ELDN

Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
ELDN

Penny Stocks To Buy Now? 3 To Watch This Week
Penny Stocks To Buy Now? 3 To Watch This Week
ELDN
About Eledon Pharmaceuticals, Inc. Common Stock
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David-Alexandre C. Gros M.D., Ph.D. | CEO & Non Independent Director | 1972 |
| Mr. Paul Sean Little | Chief Financial Officer | 1965 |
| Dr. Steven N. Perrin Ph.D. | President, Chief Scientific Officer & Non Independent Director | 1966 |
| Mr. John Herberger | Vice President of Technical Operations | — |
| Mr. Bryan E. Smith J.D. | General Counsel, Corporate Secretary & Chief Compliance Officer | 1980 |
| Dr. David Hovland Ph.D. | Chief Regulatory Officer | — |
| Ms. Marina Escudero | VP & Head of Clinical Operations | — |
| Dr. Sepideh Habibi | VP and Head of Safety & Pharmacovigilance | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.33
- MACD 12/26/9
- 0.05
- EMA 9 of MACD
- 0.01
- MACD histogram
- 0.04
- SMA 50
- $2.59
- Price above SMA 50
- EMA 50
- $2.69
- Price below EMA 50
- SMA 200
- $3.13
- Price below SMA 200
- EMA 200
- $2.77
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
No analyst data available
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.3 | +14.9 | +15.8 | +21.3 | +3.3 | +4.8 | -13.3 | -13.1 | -15.9 | +13.5 | +1.9 |



